Compare · GNPX vs SLDB

GNPX vs SLDB

Side-by-side comparison of Genprex Inc. (GNPX) and Solid Biosciences Inc. (SLDB): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. GNPX focuses on Biotechnology: Pharmaceutical Preparations, while SLDB focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • SLDB is the larger of the two at $718.8M, about 322.5x GNPX ($2.2M).
  • Both names hit the wire about 9 times in the past 4 weeks.
  • SLDB has more recent analyst coverage (19 ratings vs 0 for GNPX).
MetricGNPXSLDB
Company
Genprex Inc.
Solid Biosciences Inc.
Price
-
-
Market cap
$2.2M
$718.8M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2018
News (4w)
9
9
Recent ratings
0
19
GNPX

Genprex Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

SLDB

Solid Biosciences Inc.

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Latest GNPX

Latest SLDB